MTOR and head and neck cancer: Since high EGFR expression is a negative prognostic factor, associated with lower progression-free and overall survival rates [21], we reasoned that resistant head and neck cancer cells could be re-sensitized to ionizing radiation by targeting EGFR and mTOR with cetuximab and rapamycin, respectively.